NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib

Prior treatment

• \- Lung transplantation expected within the next 6 months.

Other

• --Included in ongoing interventional trials

• This study plans to enroll approximately 500 patients with IPF/SSc-ILD/PF-ILD who newly initiate nintedanib per physicians' discretion within 6 months before participating in the study.
• IPF cohort:
• Diagnosed with IPF during the prior 6 months before study enrollment, based on the 2018 ATS/ERS/JRS/ALAT guideline
• Patient ≥ 40 years of age
• Newly initiating nintedanib within 6 months prior to participating in the study
• Providing written informed consent prior to participating in the study
• Having further follow-up possibility with participating physician during the planned study period
• Ability to read and write in local language
  • SSc-ILD cohort:
• Diagnosed with SSc-ILD during the prior 6 months before study enrollment, based on 2013 ACR/EULAR
• Patient ≥ 20 years of age
• Newly initiating nintedanib OR not receiving nintedanib per physician's discretion (For patients who diagnosed with SSc-ILD but are not treated with nintedanib on physician's discretion, they will apply the same inclusion criteria, with baseline characteristics collected only) within 6 months prior to participating in the study
• Providing written informed consent prior to participating in the study
• Having further follow-up possibility with participating physician during the planned study period
• Ability to read and write in local language
  • PF-ILD cohort:
• Diagnosed with PF-ILD (PF-ILD patients will be enrolled only after nintedanib acquires the label approval from TFDA) during the prior 6 months before study enrollment. The definition of PF-ILD diagnosis is as follows:
  • --Patients who have ILD with a progressive phenotype, but are not diagnosed with IPF, per physician's judgment. The pathophysiology in these patients is characterized by self-sustaining fibrosis and a deterioration in lung function over time, with worsening respiratory symptoms, resistance to immune-modulatory therapies, and ultimately early mortality.
• Patient ≥ 20 years of age
• Newly initiating nintedanib OR not receiving nintedanib per physician's discretion (For patients who diagnosed with PF-ILD but are not treated with nintedanib on physician's discretion, they will apply the same inclusion criteria, with baseline characteristics collected only) within 6 months prior to participating in the study
• Providing written informed consent prior to participating in the study
• Having further follow-up possibility with participating physician during the planned study period
• Ability to read and write in local language